Aro Biotherapeutics is advancing a novel Centyrin platform that enables the targeted delivery of siRNA therapeutics to tissues beyond the liver — a long-standing limitation of traditional RNA delivery methods. Its lead candidate, ARO-101, is currently in clinical trials for Pompe disease, demonstrating promising muscle-specific knockdown in early data. With a recent Series B raise and a new CEO at the helm, Aro is expanding into autoimmune indications and preparing for multiple data catalysts in 2025.